Skip to main content
. 2020 Aug 17;12:1758835920940928. doi: 10.1177/1758835920940928

Figure 2.

Figure 2.

Forest plot of subgroup analysis of ORR in different immune checkpoint targets, line of ICI therapy, PD-L1 expression, ICI drug, subtype of breast cancer, metastatic site, CD8+ T-cell infiltration level, tumor-infiltrating lymphocytes, and combination therapy.

CI, confidence interval; CPS, combined positive score; HER2+, human epidermal growth factor receptor 2; IPS, immune cell proportion score; ORR, objective response rate, PARP inhibitors, poly ADP-ribose polymerase inhibitors; TPS, tumor proportion score; TNBC, triple-negative breast cancer.